Ebola Debates Turn Everyone into an Expert
It is a tragic truism to remark that the merits of the pharma sector are most sharply perceived only at times of deep human suffering.
It is a tragic truism to remark that the merits of the pharma sector are most sharply perceived only at times of deep human suffering. The debates engendered by the latest Ebola outbreak neatly if nastily demonstrate the point. All of a sudden, the mass media and social networks are reflecting wide public demands for more action on drug development-instead of the customary complaints that drug firms are merely cynical money-making machines. How is it possible-the question is heard over and over again-that in this day and age no vaccines or medicines exist against such terrible diseases? Why have governments been so neglectful of obvious research needs? And as the anger and frustration increase, so yesterday’s bad boys in the pharma labs become seen more as the heroes of tomorrow, the great hope for miracle cures, the saviors of the world deserving of munificent funding and strong moral support. It was thus with bird flu, with SARS, and with numerous previous health scares-and once the immediate crisis passed, the abrupt surge of sympathy for drug researchers just as abruptly subsided, and the standard narrative was resumed.
For the full version of this Applied Clinical Trials article by Peter O’ Donnell, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Bristol Myers Squibb’s Cobenfy Falls Short in Phase III Trial as Add On Therapy for Schizophrenia
April 23rd 2025In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with inadequately controlled schizophrenia did not achieve statistically significant improvements.
